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Articles
Breast cancer and hormonal contraceptives: collaborative
reanalysis of individual data on 53 297 women with breast cancer
and 100 239 women without breast cancer from
54 epidemiological studies
Collaborative Group on Hormonal Factors in Breast Cancer*
Summary
Background The Collaborative Group on Hormonal Factors
in Breast Cancer has brought together and reanalysed the
worldwide epidemiological evidence on the relation
between breast cancer risk and use of hormonal
contraceptives.
Methods Individual data on 53 297 women with breast
cancer and 100 239 women without breast cancer from 54
studies conducted in 25 countries were collected, checked,
and analysed centrally. Estimates of the relative risk for
breast cancer were obtained by a modification of the
Mantel-Haenszel method. All analyses were stratified by
study, age at diagnosis, parity, and, where appropriate, the
age a woman was when her first child was born, and the
age she was when her risk of conception ceased.
Findings The results provide strong evidence for two main
conclusions. First, while women are taking combined oral
contraceptives and in the 10 years after stopping there is a
small increase in the relative risk of having breast cancer
diagnosed (relative risk [95% Cl] in current users 1&middot;24
[1&middot;15-1&middot;33], 2p<0&middot;00001; 1-4 years after stopping 1&middot;16
[1&middot;08-1&middot;23], 2p=0&middot;00001; 5-9 years after stopping 1&middot;07
[1&middot;02-1&middot;13], 2p=0&middot;009). Second, there is no significant
excess risk of having breast cancer diagnosed 10 or more
years after stopping use (relative risk 1&middot;01 [0&middot;96-1&middot;05],
NS). The cancers diagnosed in women who had used
combined oral contraceptives were less advanced clinically
than those diagnosed in women who had never used these
contraceptives: for ever-users compared with never-users,
the relative risk for tumours that had spread beyond the
breast compared with localised tumours was 0&middot;88
(0&middot;81-0&middot;95; 2p=0&middot;002). There was no pronounced variation
in the results for recency of use between women with
different background risks of breast cancer, including
women from different countries and ethnic groups, women
with different reproductive histories, and those with or
without a family history of breast cancer. The studies
included in this collaboration represent about 90% of the
epidemiological information on the topic, and what is known
about the other studies suggests that their omission has
not materially affected the main conclusions.
Other features of hormonal contraceptive use such as
duration of use, age at first use, and the dose and type of
hormone within the contraceptives had little additional
effect on breast cancer risk, once recency of use had been
taken into account. Women who began use before age 20
had higher relative risks of having breast cancer diagnosed
while they were using combined oral contraceptives and in
the 5 years after stopping than women who began use at
older ages, but the higher relative risks apply at ages when
breast cancer is rare and, for a given duration of use, earlier
use does not result in more cancers being diagnosed than
use beginning at older ages.
Because breast cancer incidence rises steeply with age,
the estimated excess number of cancers diagnosed in the
period between starting use and 10 years after stopping
increases with age at last use: for example, among 10 000
women from Europe or North America who used oral
contraceptives from age 16 to 19, from age 20 to 24, and
from age 25 to 29, respectively, the estimated excess
number of cancers diagnosed up to 10 years after stopping
use is 0&middot;5 (95% Cl 0&middot;3-0&middot;7), 1&middot;5 (0&middot;7-2&middot;3), and 4&middot;7
(2&middot;7-6&middot;7). Up to 20 years after cessation of use the
difference between ever-users and never-users is not so
much in the total number of cancers diagnosed, but in their
clinical presentation, with the breast cancers diagnosed in
ever-users being less advanced clinically than those
diagnosed in never-users.
The relation observed between breast cancer risk and
hormone exposure is unusual, and it is not possible to infer
from these data whether it is due to an earlier diagnosis of
breast cancer in ever-users, the biological effects of
hormonal contraceptives, or a combination of reasons.
Interpretation Women who are currently using combined
oral contraceptives or have used them in the past 10 years
are at a slightly increased risk of having breast cancer
diagnosed, although the additional cancers diagnosed tend
to be localised to the breast. There is no evidence of an
increase in the risk of having breast cancer diagnosed 10 or
more years after cessation of use, and the cancers
diagnosed then are less advanced clinically than the
cancers diagnosed in never-users.
*Collaborators listed at end of article
Correspondence to: Secretariat, Collaborative Group on Hormonal
Factors in Breast Cancer, ICRF Cancer Epidemiology Unit, Gibson
Building, Radcliffe Infirmary, Oxford OX2 6HE, UK
Introduction
The use of female sex hormones as contraceptives began
in 1960, since when an estimated 200 million women
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Test for heterogeneity between study designs: X2 (2 df)=11 6; p=0 003
Test for heterogeneity between studies: X2 (33 df)=51.8; p=0’02
Figure 1: Relative risk of breast cancer in ever-users compared with never-users of combined oral
contraceptives
Separate results are given for individual studies. Each relative risk and its 99% CI is plotted as a black square and
a line. The area of the square is proportional to the amount of statistical information (ie, to the inverse of the
variance of the logarithm of the relative risk). Diamonds indicate 99% Cis for totals. The solid vertical line
represents a relative risk of 1.0 and the broken vertical line indicates the overall relative risk estimate for all
studies combmed.
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where
appropriate, the age a woman was when her first child was born and the age she was when her risk of conception
ceased.
throughout the world have used them.’ The most widely
used type of hormonal contraceptive has been the
combined oral contraceptive, which contains an oestrogen
and progestagen and is prepared from various compounds
in various doses and combinations. Other hormonal
contraceptives contain progestagen only, given orally or by
injection. Many epidemiological studies have investigated
whether hormonal contraceptives might affect breast
cancer risk 2-1,5 and the Collaborative Group on Hormonal
Factors in Breast Cancer was set up in 1992 to bring
together, reanalyse, and publish the worldwide data. The
main results are summarised here. Additional results,
together with full descriptions of the methods, the studies
and the women included, are being published elsewhere. 66
Methods
Identification of studies and collection of data
Epidemiological studies that included at least 100 women with
breast cancer and that obtained information on the use of
hormonal contraceptives and on reproductive history were eligible
for inclusion. Studies were identified from review articles, from
computer-aided literature searches, and from discussions with
colleagues. Special efforts were made to identify all studies that
included relevant information, irrespective of whether results on
hormonal contraceptives had been published. The principal
investigators of all studies identified were invited to collaborate.
Subsequently a list of studies and references was sent to
collaborators and they were asked if they knew of further studies
that were not listed; the principal investigators of those studies
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Figure 2: Relative risk of breast cancer for various indices of timing of use of combined oral contraceptives
Each analysis includes aggregated data from all studies. Variance calculations are based on floating absolute risks’1
which ascribe an appropriate vanance not only to the relative risk for each category of use but also to the relative
risk of 1.0 for never-users. The area of each square is proportional to the amount of statistical information and Cis
are drawn as white lines when they are so narrow that they lie entirely within the width of the square.
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, panty, and, where
appropriate, the age a woman was when her first child was born and the age she was when her risk of conception
ceased.
were also invited to collaborate. Few additional studies came to
light from such enquiries, and in view of the wide consultation it
seems unlikely that any substantial ones have been missed. Of the
eligible studies identified,2-65 original data were available for this
analysis from 54, of which 52 have been published.2-53 Original
data could not be retrieved for 11 studies 14-61 and one research
group declined to take part in the collaboration.65
Data for individual women were sought on sociodemographic
factors, use of hormonal contraceptives and hormone
replacement therapy, family history of breast cancer, height,
weight, age at menarche, reproductive history, menopausal status,
age at menopause, gynaecological surgery, and alcohol
consumption. Information on tumour spread was sought for
women with breast cancer. Similar data were sought from
prospective studies and from case-control studies. Prospective
studies were included by means of a nested case-control design,
with four randomly matched controls for each woman with breast
cancer.66 The availability of data on individual women permitted a
wide range of consistency checks to be made. Apparent
inconsistencies, implausibilities, or omissions were clarified with
collaborators and, where appropriate, rectified. Summary tables
and listing of the variables used in these analyses were supplied to
the investigators for checking.
Information on hormonal contraceptives, reproductive factors,
and tumour stage had been collected in fairly comparable ways in
most studies, or could be derived simply, so that use of similar
definitions across all studies was generally straightforward. The
only material difference between the studies was in the recording
of durations of use of less than a year, so analyses were repeated
with ever-users defined as women with durations of use of more
than a year, but this approach made little difference to the main
findings." Information on the type and dose of oestrogen and of
progestagen in the hormonal contraceptive that each woman had
used first, had used last, and had used for the longest period of
time was available for 27 studies3,4,9,10,12,13,15,18,24-36,28,30,33,34,37,38.40,41,48-53
(and the two unpublished studies). Preparations were grouped
into three broad categories of dose-low, medium, and high
(containing <50 )JLg, 50 jjbg, >50 jjbg, oestrogen, respectively; this
classification scheme is strongly correlated with progestagen dose
as well as with oestrogen dose." Only invasive breast cancers were
included in these analyses, and information that permitted their
classification into cancers that were localised to the breast and
those that had spread to axillary lymph nodes or to distant sites
was available for 24 studies (and the two unpublished
studies) .2,4,8,16,20-23,25,30-35,37,43,48-50,52,53
Statistical analysis
Data from different studies are combined by the Mantel-Haenszel
stratification technique." To ensure that women in one study are
compared directly only with similar women in the same study, all
analyses are stratified by study, as well as by other factors,
described below. The stratum-specific quantities that are
calculated are the standard observed minus expected (O-E)
numbers of women with breast cancer, together with their
variances, var(O-E), and covariances.66,69 Use of these simple
stratified O-E values in preference to more complex
mathematical models sacrifices some statistical power but has the
advantage of avoiding assumptions about the precise forms of any
relations in the data.
The stratified O-E values, together with their variances and
covariances, yield both statistical tests (p values) and statistical
descriptions (odds ratios, subsequently referred to as relative
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Figure 3: Relative risk of breast cancer for various indices of the timing of combined oral contraceptive use within categories of
time since last use
Format as in figure 2. Of 15 tests for heterogeneity, one within each time since last use category, two are statistically significant: age at first use in
current users (x2=12’7, df=3, p=0.005) and age at first use in women whose last use was 1-4 years ago (x2=12.6, df=3, p=0.006).
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was
when her first child was born and the age she was when her risk of conception ceased.
risks). Relative risk estimates are obtained from O-E values by
the one-step method that has been widely used in overviews of
clinical trials.7O Although this method may not be appropriate for
estimating relative risks of two-fold or greater, it should
satisfactorily estimate less extreme relative risks; when the main
analyses were repeated by maximum likelihood methods, the
results were virtually identical. 66 In analyses involving
comparisons of more than two groups, the confidence intervals
associated with these relative risks are estimated by treating the
relative risks as floating absolute risks.7! The use of floating
absolute risks does not alter the relative risk estimates, but it
reduces the variances attributed to them and reduces unwanted
covariances between the groups. This approach also attributes an
appropriate variance estimate to the group arbitrarily chosen as
the baseline group-ie, the group with relative risk set to one.
All analyses are routinely stratified by study, by centre within
study for multicentre studies, and by fine divisions of age (16, 17,
18 ... 63, 64, 65-69, 70-74, 75-79, 80-84, 85-89). Of the
remaining variables that might confound the relation between
breast cancer risk and oral contraceptive use, reproductive history
and age at which a woman ceases to be at risk of conception are
particularly important; other factors that were considered, such as
family history, ethnic group, or weight, do not confound the main
relations.66 The basic stratification procedure, therefore, also
included one variable representing reproductive history
(nulliparous women formed a separate stratum, and parous
women were cross-classified according to three divisions of age at
first birth: <20, 20-29, ===30; and two divisions of parity; 1-2, =s3)
and a second variable representing the age at which a woman
ceased to be at risk of conception (taken to be the youngest age at
which hysterectomy, tubal ligation, bilateral oophorectomy, or
natural menopause occurred, and categorised as: still at risk of
conception, <35, 35-39, 40-44, 45-49, s=50). Women with
unknown values for a particular stratification variable were
allocated to a separate stratum.
Presentation of results
For many analyses, results are presented in the form of plots of
adjusted relative risks. Because of the large number of estimates
involved, 99% CI are used in most instances, with 95% CI used
only for summarising the main findings. Each relative risk is
plotted as a black square, the area of which is inversely
proportional to the variance of the logarithm of the estimate, and
is hence an indication of the amount of statistical information
available for that particular estimate. The corresponding 99% CI
Figure 4: Age-specific relative risk of breast cancer by time
since last use of combined oral contraceptives
Format as in figure 2, within categories of age at diagnosis.
*Relative risk (given with 99% CI) relative to never-users, stratified by
study, age at diagnosis, parity, and, where appropriate, the age a
woman was when her first child was born and the age she was when her
risk of conception ceased.
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is drawn as a line; CIs that extend beyond the scale of the plot are
indicated by an arrow.
There are two main types of plot. The first type involves a two-
way comparison such as ever-use versus never-use, and gives the
results separately for all the studies with substantial amounts of
statistical information, the remaining studies being included in
the relevant other category. In these plots the overall estimate is
calculated from the sum of the study-specific values for 0 - E and
var(O-E). The second type of plot describes the results of
categorical analyses involving more than two groups, with
variances estimated via the method of floating absolute risks,
representing the aggregated results from all relevant studies.
Heterogeneity of relative risks and, where appropriate, linear
trends are assessed by X2 tests.
Results
The 54 studies contributing to these analyses were
conducted in 25 countries, mostly in Europe and North
America, but Asia, Australasia, Africa, and Latin America
were also represented. Together the studies included
53 297 women with invasive breast cancer (cases) and
100 239 women without breast cancer (controls). The
median age at diagnosis of breast cancer was 49 years, and
the median year of diagnosis was 1984. At the time of
diagnosis, 9% of women with breast cancer were younger
than 35, 25% were 35-44, 33% were 45-54, and 33%
were 55 and older. Further details of the design of each
study and of the women included are given elsewhere. 66
The analyses here excluded 22 cases and 125 controls who
were aged 15 or younger or 90 or older, and 350 cases and
1096 controls with unknown use of oral contraceptives.
Ever-use of combined oral contraceptives
Overall, 21 567 (41%) of the women with breast cancer
and 39 629 (40%) of the women without breast cancer
had ever used combined oral contraceptives. Figure 1
shows for individual studies the numbers of ever-users and
never-users and the corresponding relative risk estimates
associated with ever-use. The studies are arranged
according to study design-prospective studies, case-
control studies with population controls, and case-control
studies with hospital controls. Within the groups the
studies are listed in chronological order, according to the
median year of diagnosis of breast cancer. The results for
studies in which the information content, var(O-E), was
less than 20-0 are included in the category "other" for the
relevant study design. Overall the relative risk of breast
cancer in women who had ever used oral contraceptives
compared with women who had never used them was
slightly above 1-0, and the excess was statistically
significant (relative risk 1-07 [SD 0-02], 2p=0-00005).
There was some evidence of heterogeneity in the results
both between the individual studies and between the three
types of study design. Ever-use is, however, a crude
measure of exposure and represents different patterns of
oral contraceptive use in different studies.66 Breast cancer
risk is therefore considered in relation to various different
features of oral contraceptive use that have been thought
to be of possible importance.
Timing of exposure
Breast cancer risk is described in relation to four indices of
the timing of exposure to combined oral contraceptives-
total duration of use, age at first use, time since first use,
and time since last use. These four indices are highly
correlated,66 so if breast cancer risk is directly related to
Figure 5: Relative risk of breast cancer by time since last use
of combined oral contraceptives and in relation to childbearing
history
Format as in figure 2.
*Relative risk (given with 99% Ci) relative to never-users, stratified by
study, age at diagnosis, parity, and, where appropriate, the age a
woman was when her first child was born and the age she was when her
risk of conception ceased.
any one, it is likely to be indirectly related to the others.
To find out which of the four relations is most direct, the
one most strongly related to risk was identified, and then,
holding that one factor constant, the other three relations
were re-examined. Subsequently breast cancer risk was
investigated in relation to other indices of exposure, and
the consistency of the main findings was explored in
women of different ages and with varying background
risks of developing breast cancer.
Total duration of use (figure 2a)-A quarter of ever-
users were reported to have used oral contraceptives for
less than a year and the median total duration of use was 3
years. The relative risk was slightly above 1-0 for each of
the five broad categories of use. There was no significant
heterogeneity of relative risk of breast cancer between the
categories of duration of use, but there was a weak
indication of a trend of increasing risk with increasing
duration (p=005).
Age at first use (figure 2b) The age at starting use of
combined oral contraceptives ranged from early teens to
early 40s, with a median of 26; 14% of women had begun
use before age 20 and 17% at age 35 or older.66 The
relative risk was slightly greater than 1-0 for each of the
five age groups and was largest for women who started use
as teenagers. There was some heterogeneity in the relative
risks between the five categories of age at first use
(p=0’01) but no significant trend with increasing age at
first use.
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Figure 6: Relative risk of breast cancer by time since last use of combined oral contraceptives among women
with different characteristics
Format as in figure 2, except that SDs and Cls are based on conventional variance estimates rather than on those for floating
absolute nsks. None of the 27 tests for heterogeneity across categories of a particular characteristic is statistically
significant.
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate,
the age a woman was when her first child was born and the age she was when her risk of conception ceased.
Time since first use (figure 2c)-Most women who
had used oral contraceptives had begun use between 10
and 20 years before diagnosis of breast cancer, or
pseudodiagnosis in controls (median 16 years). The
relative risks were slightly above 1-0 in each 5-year period
of time since first use. There was evidence both of
heterogeneity of risk between the five categories (p=0-01)
and of a trend of decreasing risk with increasing time since
first use (p=0-002).
Time since last use (figure 2d)--Current users include
women who were taking oral contraceptives at the time of
diagnosis (or pseudodiagnosis) or in the preceding 12
months, and about a quarter of ever-users were included
in this category. There was evidence of an increased risk of
breast cancer being diagnosed in current users (relative
risk 1-24 [SD 0-04], 2p<0-00001) and in women who
stopped use 1-4 years previously (1-16 [0-04],
2p=0-00001), with some evidence of an increased risk 5-9
years after stopping (1-07 [0-03], 2p=0-009). For women
who stopped use 10 or more years ago, the relative risk did
not differ significantly from 1-0 (1-01 [0-02], NS).
Virtually all the information on use that ceased more than
10 years ago relates to use that ceased between 10 and 20
years ago. There was substantial heterogeneity in the
relative risks between the five categories of time since last
use (p<O’OOOOI) and a strong trend of decreasing risk with
time since last use (p<0-00001).
Each of the four tests for heterogeneity shown in
figure 2 is on four degrees of freedom and each of the tests
for trend is on one degree of freedom, so the X2 values can
be compared directly. On the basis of both types of test, of
the four factors examined, time since last use (figure 2d) is
most strongly related to breast cancer risk (for
heterogeneity, X2 =41-5, compared with 8-0, 13-4, and
13-4; and for trend, =31-7, compared with 3-9, 0-2, and
9-6).
The increased risk associated with current and recent
use and the absence of an increase in risk associated with
use that ceased 10 or more years ago remained within each
of the categories of the other three indices of exposure
(figure 3). Furthermore, when the results according to
time since last use were examined in detail to find out
whether adjustment for other possible confounders, such
as family history of breast cancer, age at menarche, or
weight, might modify the magnitudes of the relative risks
in figure 2d, none was found to do So.66
Residual effects of other indices of exposure, given time
since last use
The residual effects of the three other main indices of
exposure within each time since last use category are
shown in figure 3. No residual effects were evident for
total duration of use or for time since first use: none of the
tests for trend or heterogeneity was significant for either of
these factors within each of the five categories of time
since last use. Since breast cancer risk is more strongly
related to recent than to past use, it is possible that total
duration of use might not be relevant for women who used
oral contraceptives intermittently, with long breaks in-
between. However, analyses restricted to women whose
entire use of oral contraceptives was interrupted by less
than 24 months (pregnancies excluded) also showed no
significant trend in breast cancer risk with duration of use,
even when use was, in this sense, virtually continuous.&deg;&deg;
Also, when durations of use were calculated, restricted to
the time when women were nulliparous, there was no
relation between duration of use while nulliparous and
breast cancer risk. 66
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Figure 7: Relative risk of breast cancer in recent and past users of combined oral contraceptives
Format as in figure 1. Where the upper CI is greater than 2.0, this is indicated by an arrow.
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and,
where appropriate, the age a woman was when her first child was born and the age she was when her risk
of conception ceased.
There was, however, significant heterogeneity of risk by
age at first use in current users (p=0005) and in women
who stopped use 1-4 years ago (p=0-006), with current
and recent users who began use before age 20 having
significantly higher relative risks than women who began
at older ages (figure 3b). By contrast, among women
whose use ceased 5 or more years ago, the relative risks
were not materially affected by the age when use began.
For women who began use before age 20 and stopped use
more than 15 years ago the relative risk fell from 1-14 to
1-01 when ever-users were taken to be women with a
duration of use of greater than a year, suggesting that there
may be differential recall between cases and controls of
brief use at early ages that ceased long ago.66
The effects of other indices of the timing of exposure
were examined, including age at last use, year of first use,
and year of last use of oral contraceptives; however, no
other factor appeared to have much effect on breast cancer
risk once account had been taken of time since last use
and age at first use.66
Consistency of effect of time since last use
Although it is of interest to examine how consistent the
main findings appear to be, it should be borne in mind
that analyses restricted to particular subgroups may by
chance alone yield misleadingly irregular patterns.
Age at diagnosis The pattern of an increased relative
risk of breast cancer in recent users (ie, women whose last
use was within the previous 5 years), with no increased risk
10 or more years after cessation of use, was found
consistently at all ages (figure 4). Furthermore, for recent
users who began use after age 20, and for past users who
ceased use 5-9 or 10 or more years previously, the relative
risks did not vary significantly with age at diagnosis. For
women who began use before age 20 the relative risk
associated with current or recent use, although
consistently higher than for women who began use at older
ages, tended to decline with increasing age at diagnosis.
Within specific age groups, there was no statistically
significant trend with duration of use, once time since last
use and age at first use had been taken into account.66
Women with different background risks of breast
cancer A woman’s reproductive history affects both her
use of oral contraceptives and her risk of breast cancer.66
Although stratification for various features of reproductive
history should avoid material confounding due to those
variables, it is of interest to examine whether the results
relating to oral contraceptive use are consistent for women
with different childbearing patterns. Nulliparous women
are a special group in that there is no opportunity for the
effects of oral contraceptive use to be modified or
confounded by childbearing. In nulliparous women the
pattern of risk with respect to time since last use is similar
to that found for all women (figure 5). Moreover, among
parous women the pattern of risk is similar irrespective of
whether oral contraceptive use began before or after the
1720
Figure 8: Analyses relating extent of tumour spread among
women with breast cancer to ever-use of combined oral
contraceptives
Format as in figure 2. The reference group is women whose cancers are
localised to the breast. Relative risk estimates represent the probability
that women whose cancers have spread beyond the breast are ever-
users compared with the probability that women whose cancers are
localised to the breast are ever-users.
*Relative risk (given with 99% CI) relative to never-users, stratified by
study, age at diagnosis, parity, and, where appropriate, the age a
woman was when her first child was born and the age she was when her
risk of conception ceased.
birth of the first child (figure 5). Similar patterns of risk
with respect to time since last use of oral contraceptives
were found for women of different parity and for women
who had their first child at different ages.66 The relations
according to time since last use of oral contraceptives were
similar for women with and women without a family
history of breast cancer, for women from different
countries and ethnic groups, for women of different
heights and weights, and in premenopausal and
postmenopausal women (figure 6). None of the 27
comparisons made in figure 6 was statistically significant.
For each time since last use category (<5, 5-9, 10) an
overall test of heterogeneity was calculated by summing
the nine respective individual X2 values to give an overall X2
statistic on 14 df. The value of each of these statistics was
consistent with what would be expected if there were no
heterogeneity in the relative risks by any of the
characteristics considered. Separate analyses for recent
users who began use before and after age 20 identified no
additional variation in risk between these subgroups.66
Different studies A slightly increased relative risk of
breast cancer among recent users of combined oral
contraceptives was found consistently between the three
types of study design and between studies, although in
most individual studies the excess was not statistically
significant (figure 7a). For women who stopped use more
than 5 years ago there was also no evidence of
heterogeneity between the study designs, and only weak
heterogeneity between the individual studies (figure 7b).
Tumour spread
The breast cancers diagnosed in women who had used
combined oral contraceptives were significantly less
advanced clinically than those diagnosed in never-users.
Tumours in ever-users were less likely to have spread to
axillary lymph nodes (relative risk 0-89 [SD 004],
Test for heterogeneity between study di3siyns: X2 (2 df)=5-6; NS
Test for heterogeneity between studies: X (17 df)=19-B; NS
Figure 9: Extent of tumour spread among women with breast cancer in ever-users
compared with never-users of combined oral contraceptives
Format as in figure 1.
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis,
parity, and, where appropriate, the age a woman was when her first child was born and the age
she was when her risk of conception ceased.
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Figure 10: Relative risk of breast cancer by time since last use of combined oral contraceptives according to
extent of tumour spread
Format as in figure 2.
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where
appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.
2p=0-006) or to more distant sites (0-70 [0-11],
2p=0-006) than to be localised to the breast (figure 8).
This finding of a relative deficit of tumours that had
spread beyond the breast in ever-users did not differ
significantly across the studies with information on
tumour spread, nor according to study design (figure 9).
Both for women with localised tumours and for women
with more extensive disease, the relation with recency of
oral contraceptive use was similar to that found for all
women, the relative risks declining significantly with time
since last use (figure 10: X2 for trend, p=0’004, for each).
The relative risk of localised disease was significantly
increased in recent users and remained slightly increased
5-9 and 10 or more years after cessation of use (figure
10a). By contrast, the relative risk of cancer that had
spread beyond the breast was slightly and non-significantly
raised in recent users, and, if anything, was reduced 5-9
and 10 or more years after cessation of use (figure lOb).
These results suggest that much of the excess risk of breast
cancer in recent users is due to an excess of localised
tumours. The magnitude of the relative deficit of more
extensive disease did not vary significantly with time since
last use of oral contraceptives (test for heterogeneity
=3-1, df=2, NS; overall relative risk 0-88 [SD 004],
2p=0-002) and the relative deficit was still evident 10 or
more years after use (relative risk 0-85 [SD 0-05],
2p=0-001).
Constituents of hormonal contraceptives
Among women for whom information was available about
the particular combined oral contraceptive preparations
used, there was no significant variation in the relative risks
associated with use of specific types of oestrogen or of
progestagen, either in recent or in past users.66 When the
preparations were grouped into three broad categories
according to hormone dose there was, if anything, a
decrease in the risk of breast cancer with increasing dose
Figure 11: Relative risk of breast cancer by time since last use and hormonal dose in combined oral contraceptive last used
Format as in figure 2. Results are given separately for all cancers and for cancers that were localised to the breast and that had spread beyond the
breast. Not all studies with information about hormonal dose also provided information about tumour spread.
*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was
when her first child was born and the age she was when her risk of conception ceased.
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among women who had stopped use 10 or more years
before, largely due to a reduction in breast cancer risk
among those who had used the highest-dose preparations
(figure 11 a). There were no significant trends with
duration of use among women who had used low-dose,
medium-dose, or high-dose preparations."
The pattern of risk in relation to hormone dose was also
examined according to the extent of tumour spread. For
women whose tumours had spread beyond the breast
there was a significant decrease in risk with increasing dose
in women who stopped use more than 10 years previously
(figure 11 c) but for women with localised disease the
patterns were less pronounced and not statistically
significant (figure 1 lb). These results relate to dose in the
preparation last used, but broadly similar results were
obtained for dose in the preparation first used and that
used for the longest time.66
Hormonal contraceptives containing progestagens only
have not been widely used: oral progestagen-only
preparations had been used by only 0-8% of the study
population and injectable progestagens by only 1-5%.""
The amount of information available was limited, but the
results were broadly similar to those found for combined
oral contraceptives, with some evidence of an increase in
risk for use in the previous 5 years (relative risk 1-17
[SDO-09], p=0-06, for oral preparations; 1-17
[SD=0-13], NS, for injectable progestagens) but no
evidence of an increase in risk 10 or more years after
stopping use (0-99 [SD=0-13], NS, for oral preparations;
0-94 [SD=0-13], NS, for injectable preparations). There
were no apparent residual effects of duration of use or age
at first use, but the numbers are too small to exclude such
effects with any certainty. 66
Discussion
This review of 54 studies, conducted in 25 countries,
provides strong evidence for two main conclusions. First,
while women are taking combined oral contraceptives and
in the 10 years after they stop there is a small but definite
increase in the risk of having breast cancer diagnosed.
Second, this excess risk does not persist and there is no
evidence of an increased risk of breast cancer 10 or more
years after cessation of use (figure 12). Furthermore, the
cancers diagnosed in women who have ever used oral
contraceptives are less likely to have spread beyond the
breast than those diagnosed in women who have never
used oral contraceptives (figures 8-10). Before we
consider the implications of these findings, their reliability
and consistency are discussed.
Combining results from many studies
Because the 54 studies included here were of varied design
and were carried out among women with different baseline
risks of breast cancer in different settings, the relative risks
associated with the use of oral contraceptives might have
been expected to differ substantially between the study
designs and between the individual studies. However, after
recency of use was taken into account there was no
pronounced variability between studies or study designs
(figure 7) or between women with different background
risks of breast cancer (figures 5 and 6).
Combining results from many studies has the obvious
advantage of reducing random errors. Furthermore,
because chance alone would make some studies suggest
one conclusion and others suggest another conclusion,
Figure 12: Relative risk of breast cancer by time since last use
of combined oral contraceptives
Relative risk (given with 95% CI) relative to never-users, stratified by
study, age at diagnosis, parity, age at first birth, and age at which risk
of conception ceased.
systematic analysis of the worldwide evidence reduces
biases that can be produced by undue emphasis on
particular studies with extreme results. Although the 54
studies included here were of varied size, no single study
was so large as to dominate the overall results.
The data presented here represent about 90% of the
worldwide epidemiological evidence on breast cancer risk
and use of hormonal contraceptives. What is known about
the 12 studies for which data were not included suggests
that their results would have been consistent with the main
findings. The pooled estimate of the relative risk of ever-
use of oral contraceptives compared with never-use from
those studies"-15 was 1-07 (SD 0-04), which is identical to
the estimate of 1-07 found for the data included (figure 1).
Five of these studies54,57,59,62,65 published data on recent use
of oral contraceptives, and the pooled estimate of the
relative risk associated with current use or recent use
(usually representing use in the last 3 years) was 1-16 (SD
0-11) which again resembles our estimate of 1-16 for
recent users (figure 7a). No omitted study reported an
increase in breast cancer many years after cessation of oral
contraceptive use-in fact, seven54-59,63 were among the
earliest studies ever done, and so could not have produced
much evidence of any long-term effect to modify the
findings reported here for past users. The main results are
therefore unlikely to be materially affected by the omission
of about 10% of the epidemiological evidence.
Bias, confounding, and chance
As well as the biases that could be caused by undue
emphasis on particular studies, selective emphasis on
particular subgroups can also introduce bias. Despite
the large amount of information available, some
untrustworthy irregularities inevitably emerge when data
are subdivided in many ways. Nevertheless, it is necessary
to divide the data into many subgroups, as has been done
here, to examine which patterns of use are associated with
risk, and how that risk varies with age, family history, and
so on. This report contains some 400 relative risk
estimates and their respective confidence intervals. A few
apparently heterogeneous findings are observed but it is
important to bear in mind that at least part of this
apparent variation in risk between subgroups is likely to be
due to chance.
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Biases can also be introduced if there is differential
reporting of oral contraceptive use by cases and controls.
The reporting of very short durations of use is a potential
source of bias, because a quarter of the ever-users were
reported as having used oral contraceptives for less than a
year and the proportion of such users varied substantially
from one study to another. 116 Even a slight tendency for
short-duration use to be reported in different ways by
cases and controls could bias the results; to assess the
potential relevance of this bias, the main analyses were
repeated with ever-users defined as women with durations
of use of more than a year. 66 The main conclusions about
the relation of breast cancer with respect to time since last
use were not altered. There was, however, some
suggestion that there may be slight differences in the
reporting of brief use at young ages that ceased long ago.
Another potential bias is that women who have used oral
contraceptives may have their cancer detected earlier than
women who have never used oral contraceptives
(discussed later).
To minimise the potential for confounding, all analyses
were simultaneously stratified for study, age at diagnosis in
single years, parity, and, where appropriate, the age a
woman was when her first child was born, and the age
when her risk of conception ceased. This fine stratification
means that no direct comparisons were made between
women in one study and women in another and that the
contraceptive history of a woman with breast cancer is
compared only with that of control women in the same
study who were exactly the same age as her and had a
similar reproductive history. Although the stratification is
fine enough to avoid any material confounding by these
factors, it was not excessively fine, since the standard
deviations of the main risk estimates are still small.
Adjustment for other factors did not alter the associations
described here.66
Since the various measures of the timing of exposure to
oral contraceptives are highly correlated, failure to stratify
by time since last use and age at first use can confound the
associations with other related exposures."" For example,
duration of oral contraceptive use in young women is
highly correlated with time since last use and age at first
use, and analyses that do not stratify by those factors can
produce apparent associations between breast cancer risk
and duration of use.
Excess risk in recent users
The increased risk of breast cancer being diagnosed
among current users and among women whose use ceased
1-4 years previously is each based on large numbers and is
highly statistically significant. These findings were seen
consistently between studies, although few studies showed
a significant excess in their own right (figure 7a). The
relative risk declined with time after cessation of use and
was still slightly increased 5-9 years after cessation of use
(figure 12). The excess risk in recent users was largely
associated with tumours localised to the breast (figure 10).
Few factors appeared to modify the relative risks
associated with recent use of oral contraceptives, despite
the large number of possibilities considered. 1,6 For
example, there was no strong evidence of variation in risk
with duration of oral contraceptive use, or with respect to
family history of breast cancer, ethnic origin, age at
menarche, height, weight, menopausal status, or alcohol
use. The only factor identified that had much effect on the
relative risk associated with recent use of oral
contraceptives was age at first use (figure 3b). For recent
users the relative risks were greater for those who began
before age 20 than for those who began at later ages
(figure 3b) and tended to decline with increasing age at
diagnosis (figure 4).
Overall, the risk of breast cancer in recent users is not
significantly related to the dose or type of hormone within
the hormonal contraceptive used.66 The limited
information available for hormonal contraceptives
containing progestagens alone suggests that use of oral or
injectable progestagen-only preparations might also
involve a small increase in breast cancer being diagnosed
in recent users.
No adverse effect in the long term
There is no evidence of an excess risk of breast cancer 10
or more years after cessation of use overall (relative risk
1-01 [SD 002]). The lack of an increased risk 10 or more
years after stopping is seen fairly consistently in individual
studies and in most subgroups of women. The cancers
diagnosed 10 or more years after cessation of use are,
however, slightly less likely to have spread beyond the
breast than the cancers diagnosed in never-users (figure
10).
Although the absence of an increase in breast cancer
risk 10 or more years after cessation of oral contraceptive
use is reliably established, the available information is still
somewhat limited. Oral contraceptives have been widely
used only since the 1960s and most of the cancers
included in these analyses were diagnosed during the
1980s. Thus there is still little information beyond 20
years after cessation of use. Moreover, most women who
stopped use 10 or more years ago had used oral
contraceptives only for short periods (figure 3a) and
tended to have used medium-dose or high-dose
preparations (figure 11).
Possible explanations of findings
The relations observed here between cancer risk and
exposure are unusual, since the risk increases soon after
first exposure, does not increase with duration of
exposure, and returns to normal 10 years after cessation of
exposure. Such a pattern seems incompatible with a
genotoxic effect. An increased risk in recent users is,
perhaps, compatible with the classic concept of the
promotion of tumours that have already been initiated.
The deficits in risk seen in certain groups 10 or more years
after cessation of exposure, if confirmed, might be
indicative of analogous effects of hormonal contraceptives
and of childbearing on breast cancer risk.
The finding that the breast cancers in women who had
used oral contraceptives were less advanced clinically than
those in never-users raises the possibility that users of oral
contraceptives may have had their cancers diagnosed
earlier in the development of the disease than would
otherwise have happened. If this were so, the implication
from these data is that women who have used oral
contraceptives continue to have their cancers diagnosed
earlier than never-users even many years after use ceases
because the relative excess of localised tumours is similar
in current and past users and does not vary significantly
with time since last use."" Alternatively, oral contraceptives
might affect the rate of growth of tumours and their
tendency to metastasise. It is not possible to infer from
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Figure 13: Estimated cumulative number of breast cancers diagnosed in never-users and in women who used
oral contraceptives at various ages
Estimated numbers for 10000 women in Europe or North America; details of calculations are given elsewhere.66 Note: the
estimated numbers for ever-users and never-users are so similar in some age ranges that they overlap almost entirely.
these data whether the patterns of risk observed are due to
an earlier diagnosis of breast cancer in ever-users, the
biological effects of hormonal contraceptives, or a
combination of both factors. Further information is
needed on whether women who have used oral
contraceptives are more likely to have their cancers
detected earlier, how long the deficit of advanced disease
persists, its relation to hormone dose, and whether there is
differential survival in ever-users and never-users.
There is no clear explanation for the finding that the
relative risk associated with current use or use that ceased
in the previous 5 years is higher for women who began use
before age 20 than after that age. This finding could reflect
a comparatively greater effect of the artificial preparations
before adult hormone secretion patterns are fully
established. Alternatively, it could be partly due to
differential reporting of use at young ages by cases and
controls, chance, or a combination of reasons. The
available data for use beginning before age 20 indicate that
there is no substantial increase of breast cancer risk in this
subgroup more than 5 years after cessation of use, but
virtually all the existing information relates to women
younger than 45. In the next decade women who began
use as teenagers will reach their late 40s and early 50s,
when breast cancer is more common. When the new data
on the long-term effects of early use become available it
will be necessary to re-examine the worldwide evidence.
Calculated numbers of breast cancers diagnosed in
ever-users compared with never-users
Even though it is not possible to infer from these data
whether the findings described here are due to the earlier
diagnosis of breast cancer among ever-users, the biological
effects of hormonal contraceptives, or a combination of
reasons, the approximate number of cancers that would be
diagnosed in women who have used oral contraceptives
can be calculated. Combining the estimates of relative risk
by time since last use suggested by these analyses with
incidence rates of breast cancer in various populations,
calculations were made of the cumulative number of
breast cancers diagnosed in women who had used oral
contraceptives at various ages for various durations.66
Figure 13 shows, as an example, the calculated cumulative
numbers of cancers diagnosed in 10 000 women in Europe
or North America who used oral contraceptives from age
16 to 19, from age 20 to 24, and from age 25 to 29,
compared with women who had never used them. There is
a small excess in the estimated number of cancers
diagnosed in the period from starting oral contraceptive
use up to 10 years after stopping, but by 20 years after
Figure 14: Estimated cumulative number of breast cancers
diagnosed in never-users and in women who used oral
contraceptives from age 25 to 29, according to extent of
tumour spread
Estimated numbers for 10000 women in Europe or North America;
details of calculations are given elsewhere.66
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stopping there is no significant difference between ever-
users and never-users in the cumulative numbers
diagnosed. For women in developing countries the
incidence of breast cancer is lower than in Europe or
North America and thus, even with the same relative risks,
the differences between the calculated results for ever-
users and never-users in the cumulative numbers of breast
cancers diagnosed are even smaller than those shown in
figure 13.66
It can be seen in figure 13 how rare breast cancer is
among women in their 20s and 30s compared with older
ages and that the excess number of cancers diagnosed in
current and recent users of oral contraceptives is small in
relation to the cumulative risk of breast cancer. In
particular, the comparatively higher relative risk in current
or recent users who began use before age 20 (figure 3b)
which was used to calculate the cumulative incidence
associated with oral contraceptive use from age 16 to 19 in
figure 13, act at an age when the background incidence of
breast cancer is low.
The calculated cumulative number of breast cancers
diagnosed in 10 000 women in Europe or North America
in the period between starting use and 10 years after
stopping is approximately 4-5 for use from age 16 to 19
compared with 4-0 in 10000 never-users of the same age
over the same period; 17-5 compared with 16-0 for use
from age 20 to 24; 48-7 compared with 44-0 for use from
age 25 to 29; 110 compared with 100 for use from age 30
to 34; 180 compared with 160 for use from age 35 to 39;
and 260 compared with 230 for use from age 40 to 44.
These numbers correspond to cumulative excesses of 0-5
(SD 0-1), 1-5 (0-4), 4-7 (1-0), 11-1 (2-1), 21-0 (3-6), and
32-0 (5-0) per 10000, respectively. 66 Thus for a given
duration of use, earlier use does not not lead to a greater
number of cancers being diagnosed. Indeed, the
calculated cumulative excess increases with increasing age
at last use, and, as shown elsewhere, 16 for a given age at
last use the excess is little affected by a woman’s prior
duration of oral contraceptive use. In addition, as
illustrated in figure 14, virtually all the excess cancers
diagnosed up to 10 years after cessation of use are
localised to the breast, and there is little or no evidence of
a cumulative excess of tumours that had spread beyond
the breast."
The calculated cumulative number of breast cancers
diagnosed up to 20 years after cessation of oral
contraceptive use is largely influenced by the results for
use that stopped between 10 and 20 years ago, because
breast cancer incidence increases rapidly with age. There
is no excess risk of having breast cancer diagnosed
between 10 and 20 years after stopping and, indeed there
may be a slight deficit in the number of breast cancers
diagnosed during that period, which could offset some of
the excess diagnosed up to 10 years after stopping."
Furthermore, the cancers diagnosed between 10 and 20
years after cessation of use are less likely to have spread
beyond the breast than are the cancers diagnosed in never-
users. Hence, 20 years after cessation of oral contraceptive
use the difference between ever-users and never-users is
not so much in the cumulative number of breast cancers
diagnosed, but in the clinical presentation of the tumours.
This is illustrated in figure 14 for women who used oral
contraceptives from age 25 to 29, where it can be seen that
up to 20 years after cessation of use (ie, by age 50) there is
a small excess of localised cancers and a small deficit of
cancers that have spread beyond the breast but there is
little difference in the total number of breast cancers
diagnosed. Tumours that are localised to the breast are
associated with a better survival than tumours that have
spread beyond it,7O but without follow-up information on
the women with breast cancer it is not possible to be sure
whether oral contraceptive use increases, decreases, or has
no effect on cumulative mortality from breast cancer.
As yet there is little information about use that ceased
more than 20 years ago. Consequently, the conclusion
from these calculations can be only that up to 20 years
after cessation of use there is little difference in the
cumulative incidence of breast cancer between women
who have used and have not used oral contraceptives.
Implications
For women using, or contemplating the use of, oral
contraceptives there is a small increase in the risk of having
breast cancer diagnosed while taking oral contraceptives
and during the 10 years thereafter. The older women are
at last use, the larger the number of excess cancers
diagnosed during this period is likely to be, although the
additional cancers diagnosed are mainly ones that are
localised to the breast.
For women who have used hormonal contraceptives in
the past these results indicate that 10 years after cessation
of use there is little or no increase in the risk of having
breast cancer diagnosed, and that the cancers diagnosed
are less advanced clinically than the cancers diagnosed in
women who have never used oral contraceptives.
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